SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE is supported by strong underlying procedure growth, with 3Q26 revenue of $55.7 million up about 15% year over year, U.S. volumes up 20%, gross margin at 79.3%, and adjusted EBITDA of $3.0 million beating expectations. The outlook is strengthened by reaffirmed 2026 revenue guidance of $231 million to $233 million, implying roughly 20% 4Q growth at the midpoint, while lower operating expense growth to 10.5% should aid profitability. Management’s launch of Onyx, expanding reimbursement, a growing surgeon base of 1,770 active physicians, and a capital-light, high-margin model all support continued above-peer growth and a path toward improved cash generation.

SI-BONE is exposed to structural risks that weaken its long-term fundamentals, including unfavorable reimbursement changes, heavy dependence on a single orthopedic anatomical location, and intensifying competition that could pressure adoption and utilization. Its bear case assumes only single-digit U.S. revenue growth with stalled margin improvement, suggesting that the company may struggle to scale profitably even as it commercializes products like iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite. Additional downside comes from competitive launches, iFuse patent expirations, poor sales force execution, and unfavorable market dynamics, all of which could slow the ramp toward profitability and support a low EV/sales framework versus 2027E expectations.